 authors investigated dependence increasing serum oncomarkers CEA, Cyfra-21, NSE, TU M2-PK survival 739 patients nonsmall cell lung cancer. tests determination content CEA, Cyfra-21, NSE blood serum low sensitivity little use diagnosis lung cancer. tests simplicity low cost used detection groups patients preliminarily diagnosed nonsmall cell lung cancer needing additional methods examination exact staging disease exclusion remote metastases active using adjuvant method treatment. use tumor pyruvate kinase perspective clinical oncopulmonology. However, due low specificity, experiences required using oncomarker group patients nonsmall cell lung cancer.